HNSBF (Hansa Biopharma AB) E10: $-1.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSBF Hansa Biopharma AB HNSBF
56 GF Score
Price $2.90
GF Value $2.22
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB E10?

Hansa Biopharma AB HNSBF 56 E10 is $-1.00 as of Mar. 2026. GuruFocus rates HNSBF with a GF Score™ of 56/100 and a GF Value™ of $2.22 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Hansa Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.207. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Hansa Biopharma AB was -10.30% per year. The lowest was -17.10% per year. And the median was -13.70% per year.

As of today (2026-07-14), Hansa Biopharma AB's current stock price is $2.90. Hansa Biopharma AB's E10 for the quarter that ended in Mar. 2026 was $-1.00. Hansa Biopharma AB's Shiller PE Ratio of today is .


Hansa Biopharma AB  (OTCPK:HNSBF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Hansa Biopharma AB E10 Related Terms


Hansa Biopharma AB E10 Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB E10 Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.74 -0.81 -0.79 -0.80 -0.92

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.22 -0.82 -0.92 -1.00

HNSBF vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Shiller PE Ratio falls into.


HNSBF
56GF Score
Hansa Biopharma AB HNSBF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.207/133.5600*133.5600
=-0.207

Current CPI (Mar. 2026) = 133.5600.

Hansa Biopharma AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.113 101.019 -0.149
201609 -0.097 101.138 -0.128
201612 -0.106 102.022 -0.139
201703 -0.142 102.022 -0.186
201706 -0.148 102.752 -0.192
201709 -0.132 103.279 -0.171
201712 -0.160 103.793 -0.206
201803 -0.149 103.962 -0.191
201806 -0.176 104.875 -0.224
201809 -0.180 105.679 -0.227
201812 -0.231 105.912 -0.291
201903 -0.195 105.886 -0.246
201906 -0.219 106.742 -0.274
201909 -0.243 107.214 -0.303
201912 -0.294 107.766 -0.364
202003 -0.237 106.563 -0.297
202006 -0.266 107.498 -0.330
202009 -0.313 107.635 -0.388
202012 -0.283 108.296 -0.349
202103 -0.274 108.360 -0.338
202106 -0.355 108.928 -0.435
202109 -0.386 110.338 -0.467
202112 -0.405 112.486 -0.481
202203 -0.325 114.825 -0.378
202206 -0.381 118.384 -0.430
202209 -0.316 122.296 -0.345
202212 -0.309 126.365 -0.327
202303 -0.374 127.042 -0.393
202306 -0.445 129.407 -0.459
202309 -0.430 130.224 -0.441
202312 -0.230 131.912 -0.233
202403 -0.399 132.205 -0.403
202406 -0.315 132.716 -0.317
202409 -0.150 132.304 -0.151
202412 -0.371 132.987 -0.373
202503 -0.056 132.825 -0.056
202506 -0.265 133.699 -0.265
202509 -0.187 133.480 -0.187
202512 -0.174 133.390 -0.174
202603 -0.207 133.560 -0.207

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.00 mean?
Hansa Biopharma AB (HNSBF) has a E10 of $-1.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's E10 too high?
Hansa Biopharma AB's current E10 is $-1.00. Overall, Hansa Biopharma AB has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's E10 compare to VRTX and REGN?
Hansa Biopharma AB's E10 of $-1.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current E10 is $-1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (HNSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.22, compared to a current price of $2.90 — trading 30.6% above its estimated fair value. The current E10 is $-1.00. Hansa Biopharma AB's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Hansa Biopharma AB (HNSBF), the current E10 is $-1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (HNSBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of $2.90 is trading 30.6% above its estimated GF Value™ of $2.22. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for HNSBF:

  • E10: $-1.00
  • GF Value™: $2.22 vs. price of $2.90 (30.6% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the HNSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
56GF Score

Get the complete analysis for HNSBF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$2.22
GF Value